Inflammatory and locally advanced breast cancer

Management of Breast Diseases

Volumn , Issue , 2010, Pages 391-415

  Gonzalez Angulo, Ana Maria ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887931926     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-69743-5_21     Document Type: Chapter

References (177)

1. Seidman H (1987) Survival experience in the breast cancer detection demonstration project. CA Cancer J Clin. 37:528-90
2. Zeicner GI, Mohar BA, Ramirez U M T (1993) Epidemiologia del cancer de mama en el instituto nacional de cancerologia (1989-1990). Cancerologia. 35:810-4
3. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B, Kurkure A, Anderson BO; Global Summit Treatment and Allocation of Resources Panel (2006) Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 12(Suppl 1):S38-53
4. American College of Surgeons National Cancer Data Base (2002) http://www.facs.org/cancer/publicncdb.html. Accessed 5 Jan 2008
5. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results (SEER) program at the National Cancer Institute. J Natl Cancer Inst. 97:966-75
6. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2006) Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 22:9-23
7. Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH (2003) Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 7:398-404
8. Mourali N, Muenz LR, Tabbane F, Belhassen S, Bahi J, Levine PH (1980) Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 46:2741-6
9. Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol. 16:3731-5
10. Anderson WF, Chu KC, Chang S (2003) Inflammatory breast cancer and non-inflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 21:2254-9
11. Haagensen CD. Inflammatory carcinoma, diseases of the breast. Philadelphia, PA: W. B. Saunders; 1956. p. 488-98
12. Leitch A. Peau d'orange in acute mammary carcinoma: its cause and diagnostic value. Lancet. 1:861-3
13. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol. 10:1014-24
14. Lee BJ, Tannenbaum EN (1924) Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 39:580-95
15. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Halvie M, August D, Wicha M, Lichter A, Pierce LJ (1997) Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol. 15:2873-81
16. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 20:3628-36
17. Denoix P (1970) The institute's contribution to the definition of factors guiding the choice of treatment: phase I development. In: Denoix P (ed) Treatment of malignant breast tumors. Vol. 32. Springer, Berlin
18. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M (2008) Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 109(3):417-26
19. Klefström P, Gröhn P, Heinonen E, Holsti L, Holsti P (1987) Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. Cancer. 60:936-42
20. Gröhn P, Heinonen E, Klefström P, Tarkkanen J (1984) Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer. 54:670-4
21. Derman DP, Browde S, Kessel IL, De Moor NG, Lange M, Dansey R, Seymour L, Bezwoda WR (1989) Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 17:257-61
22. Schaake-Koning C, van der Linden EH, Hart G, Engelsman E (1985) Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys. 11:1759-63
23. Rubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R, van der Schueren E, Papadiamantis J, Vassilaros SD, Wildiers J et al (1989) Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol. 25:667-78
24. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1:53-9
25. Hortobagyi GN, Blumenschein GR, Tashima CK. Multidisciplinary treatment of locally advanced (stage III) breast cancer. Proc Am Soc Clin Oncol. 1978;19:361; abstr c-219
26. Schick P, Goodstein J, Moor J, Butler J, Senter KL (1983) Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol. 22:278-82
27. Perloff M, Lesnick GJ (1982) Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg. 117:879-81
28. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 47:3889-94
29. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F (1983) Multimodal treatment of locoregionally advanced breast cancer. Cancer. 51(5):763-8
30. Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single center. Ann Oncol. 2:347-54
31. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast-conserving surgery: preliminary results of a randomized trial. Eur J Cancer. 30 A: 645-52
32. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM, Chepic OF (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 5:591-5
33. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 13:547-52
34. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 15:2483-93
35. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:2672-85
36. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicenter randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 10:47-52
37. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 19:4224-37
38. Valagussa P, Zambetti M, Bignami P, de Lena M, Varini M, Zucali R, Rovini D, Bonadonna G (1983) T3b-T4 breast cancer: factors affecting results in combined modality treatments. Clin Exp Metastasis. 1:191-202
39. Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL (1980) Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer. 16:351-6
40. Conte PF, Alama A, Bertelli G, Canavese G, Carnino F, Catturich A, Di Marco E, Gardin G, Jacomuzzi A, Monzeglio C (1987) Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer. 40:490-4
41. Jacquillat C, Baillet F, Weil M, Auclerc G, Housset M, Auclerc M, Sellami M, Jindani A, Thill L, Soubrane C (1988) Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer. 61:1977-82
42. Pawlicki M, Skolyszewski J, Brandys A (1983) Results of combined treatment of patients with locally advanced breast cancer. Tumori. 69:249-53
43. Balawajder I, Antich PP, Boland J (1983) An analysis of the role of radiotherapy alone and in combination with chemotherapy and surgery in the management of advanced breast carcinoma. Cancer. 51:574-80
44. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O; Aberdeen Breast Group (2002) Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 3(Suppl 2):S69-74
45. von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 23:2676-85
46. von Minckwitz G, Blohmer JU, Loehr A, Raab G, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Schickling O, Zuna I, Kaufmann M. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy. First results of the phase III GEPARTRIO-Study by the German Breast Group. Breast Cancer Res Treat. 2005;94(Suppl 1):S19; abstr 38
47. von Minckwitz G, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study " GeparQuattro". Breast Cancer Res Treat. 2007;106(Suppl 1):S21; abstr 79
48. Veronesi A, Frustaci S, Tirelli U, Galligioni E, Trovò MG, Crivellari D, Magri MD, Tumolo S, Grigoletto E (1981) Tamoxifen therapy in postmenopausal advanced breast cancer: efficacy at the primary tumor site in 46 evaluable patients. Tumori. 67:235-8
49. Gazet JC, Ford HT, Coombes RC (1991) Randomized trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br J Cancer. 63:279-82
50. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, Asmar L, Frye D, McNeese MD, Hortobagyi GN (2000) Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 88:2054-60
51. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 19:3808-16
52. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 24:1831-8
53. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 4:348-53
54. Gianni L, Semiglazov V, Manikhas GM, Eiermann W, Lluch A, Tjulandin S, Feyereislova A, Vanhauwere B, Valagussa P, Baselga J. Neoadjuvant trastuzumab plus doxorubicin, paclitaxel and CMF in locally advanced breast cancer (NOAH trial): Feasibility, safety and antitumor effects. Proc Breast Cancer Symp. 2007;1:131; abstr 144
55. Bozzetti F, Saccozzi R, De Lena M, Salvadori B (1981) Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 18:355-61
56. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reyno L; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. 2004;170:983-94
57. Atkins HL, Horrigan WD (1961) Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy. Am J Roentgenol Radium Ther Nucl Med. 85:860-4
58. Toonkel LM, Fix I, Jacobson LH, Bamberg N, Wallach CB (1986) Locally advanced breast carcinoma: results with combined regional therapy. Int J Radiat Oncol Biol Phys. 12:1583-7
59. Perez CA, Fields JN, Fracasso PM, Philpott G, Soares RL Jr, Taylor ME, Lockett MA, Rush C (1994) Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 74:466-76
60. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN (1997) Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Center. Cancer Chemother Pharmacol. 40:321-9
61. Bauer RL, Busch E, Levine E, Edge SB (1995) Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 2:288-94
62. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365:1687-717
63. Singletary SE, Ames FC, Buzdar AU (1994) Management of inflammatory breast cancer. World J Surg. 18:87-92
64. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN (1995) Combined modality treatment of stage III and inflammatory breast cancer. M. D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 4:715-34
65. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN (2001) Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 92:1775-82
66. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN (2004) Paclitaxel improves the prognosis in estrogen receptor-negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 4:415-9
67. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1673-84
68. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1659-84
69. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, Lorusso P, Lombardi DP, Ben Ahmed S, Citrin DL, Desilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2(HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 26 (7):1066-72
70. Cristofanilli M, Boussen H, Baselga J, Lluch A, Ben Ayed F, Friaha M, Ben Ahmed S, Hurley J, Johnston S, Kaufman B, Findlay M, Olopade O, Shannon C, Harris J, Stein S, Spector N. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res Treat. 2006;100(Suppl 1):S5; abstr 1
71. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification 9 2004. Clin Cancer Res. 10:7965-71
72. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 24:769-77
73. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC (2007) Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res. 13:5862-8
74. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 21:2492-9
75. http://www.clinicaltrials.gov/ct2/results?term=breast+canc er+AND+FTI+inhibitors. Accessed 02 Aug. 2008
76. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR (1999) Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 85:93-9
77. Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J (1999) Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol. 17:2006-14
78. Schwartzberg L, Weaver C, Lewkow L, McAneny B, Zhen B, Birch R, West W, Tauer K, Buckner C (1999) High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant. 24:981-7
79. Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH (2004) Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 22:1839-48
80. Haagensen CD, Stout AP (1943) Carcinoma of the breast: II. Criteria of operability. Ann Surg. 118:859-70
81. Baclesse F (1965) Five-year results in 431 breast cancers treated solely by roentgen rays. Ann Surg. 161:103-4
82. Zucali R, Uslenghi C, Kenda R, Bonadonna G (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 37:1422-31
83. Harris JR, Sawicka J, Gelman R, Hellman S (1983) Management of locally advanced carcinoma of the breast by primary radiation therapy. Int J Radiat Oncol Biol Phys. 9:345-9
84. Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, Harris JR (1987) Primary radiation therapy for locally advanced breast cancer. Cancer. 60:1219-25
85. Fletcher GH, Montague ED (1965) Radical irradiation of advanced breast cancer. Am J Roentgenol Radium Ther Nucl Med. 93:573-84
86. Baclesse F. Roentgen therapy as the sole method of treatment of cancer of the breast. Am J Roentgenol Radium Ther Nucl Med. 1949;62(3):311-9; discussion 349-54
87. Spanos WJ Jr, Montague ED, Fletcher GH (1980) Late complications of radiation only for advanced breast cancer. Int J Radiat Oncol Biol Phys. 6:1473-6
88. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA (2004) Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 22:4691-9
89. Singletary SE, McNeese MD, Hortobagyi GN (1992) Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 69:2849-52
90. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK (2001) Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 182:601-8
91. Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bougnoux A, Lemarié E, Fignon A, Body G, Bougnoux P, Lansac J et al (1993) Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys. 26:37-42
92. Héry M, Namer M, Moro M, Boublil JL, La Lanne CM (1986) Conservative treatment (chemotherapy/radiotherapy) of locally advanced breast cancer. Cancer. 57:1744-9
93. Touboul E, Lefranc JP, Blondon J, Ozsahin M, Mauban S, Schwartz LH, Schlienger M, Laugier A, Guerin RA (1992) Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol. 25:167-75
94. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 82:1539-45
95. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM, McFarlane J (1994) Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 73:362-9
96. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ (1999) Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 44:989-90
97. Taylor ME, Haffty BG, Shank BM, Halberg FE, Martinez AA, McCormick B, McNeese MD, Mendenhall NP, Mitchell SE, Rabinovitch RA, Solin LJ, Singletary SE, Leibel S, Recht A (2000) Postmastectomy radiotherapy. American college of radiology. ACR appropriateness criteria. Radiology. 215(Suppl):1153-70
98. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN (2002) Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 20:17-23
99. Buchholz TA, Strom EA, Perkins GH, McNeese MD (2002) Controversies regarding the use of radiation after mastectomy in breast cancer. Oncologist. 7:539-46
100. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA (2003) Hortobagyi GN (2003) Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 98:1150-60
101. Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, Roucayrol AM, Ganem G, Huart J, Pierquin B (1988) Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer. 61:1096-103
102. Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N (1989) Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 17:249-55
103. Perez CA, Fields JN (1987) Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology (Williston Park). 1:81-94
104. Barker JL, Montague ED, Peters LJ (1980) Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer. 45:625-9
105. Attia-Sobol J, Ferrière JP, Curé H, Kwiatkowski F, Achard JL, Verrelle P, Feillel V, De Latour M, Lafaye C, Deloche C et al (1993) Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 29 A: 1081-8
106. Thomas F, Arriagada R, Spielmann M, Mouriesse H, Le Chevalier T, Fontaine F, Tursz T (1995) Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 76:2286-90
107. Moore MP, Ihde JK, Crowe JP Jr, Hakes TP, Kinne DW (1991) Inflammatory breast cancer. Arch Surg. 126:304-6
108. Chu AM, Wood WC, Doucette JA (1980) Inflammatory breast carcinoma treated by radical radiotherapy. Cancer. 45:2730-7
109. Clark GM (2000) Prognostic and predictive factors. In: Harris JR (ed) Diseases of the Breast., 2nd edn. Lippincott Williams and Wilkins, Philadelphia
110. Stewart JF, King RJ, Winter PJ, Tong D, Hayward JL, Rubens RD (1982) Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur J Cancer Clin Oncol. 18:1315-20
111. Gardin G, Rosso R, Campora E, Repetto L, Naso C, Canavese G, Catturich A, Corvò R, Guenzi M, Pronzato P et al (1995) Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer. 31 A: 1428-33
112. Silvestrini R, Daidone MG, Valagussa P, Salvadori B, Rovini D, Bonadonna G (1987) Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep. 71:375-9
113. Gruber G, Ciriolo M, Altermatt HJ, Aebi S, Berclaz G, Greiner RH (2004) Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer. 109:144-8
114. Jardines L, Haffty BG, Theriautl RL (1999) Locally advanced, locally recurrent and metastatic breast cancer. In: Pazdur R, Coia LR, Hoskins WJ, Wagman Ld (eds) Cancer management. a multidisciplinary approach., 3rd edn. PRR, Melville, NY, pp 73-88
115. Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M (1989) Cell kinetics and hormonal receptor status in inflammatory breast carcinoma: comparison with locally advanced disease. Cancer. 64:1922-7
116. Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2:423-9
117. Turpin E, Bièche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espié M, Marty M, Lidereau R, Vidaud M, de Thé H (2002) The increased incidence of ERBB2 over expression and TP53 mutation in inflammatory breast cancer. Oncogene. 21:7593-7
118. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR (1991) Genetic basis for p53 over expression in human breast cancer. Proc Natl Acad Sci USA. 88:5006-10
119. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F (2005) P53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 69:145-50
120. Riou G, Lê MG, Travagli JP, Levine AJ, Moll UM (1993) Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J. Natl. Cancer Inst. 85:1765-7
121. Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, Yamamura Y, Hortobagyi GN, Cristofanilli M (2004) p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 10:6215-21
122. Kleer CG, van Golen KL, Braun T, Merajver SD (2002) Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 14:458-64
123. Tomlinson JS, Aplaugh ML, Barsky SH (2001) An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 61:5231-41
124. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH (2002) Cooperative role of E-cadherin and sialyl-lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 21:3631-43
125. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 88:718-25
126. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 10:7965-71
127. Kleer CG, Van Golen KL, Merajver SD (2002) Molecular biology of breast cancer metastasis Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2:423-9
128. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, Wakasugi H (2001) Absence of endothelial cells, central necrosis and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 61:445-51
129. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB (2005) Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res. 11:7637-42
130. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P (1997) Promoting apoptosis: a novel activity associated with the cylin-dependent kinase inhibitor p27. Cancer Res. 57:5441-5
131. Durand B, Gao FB, Raff M (1997) Accumulation of the cycline-dependent kinase inhibitor p27/kip1 and the timing of oligodendrocyte differentiation. EMBO J. 16:306-17
132. St Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS (1996) Impact of the cylindependent kinase inhibitor p27kip1 on resistance of tumor cells to anti cancer agents. Nat Med. 2:1204-10
133. Gonzalez-Angulo AM, Guarneri V, Gong Y, Cristofanilli M, Morales-Vasquez F, Sneige N, Hortobagyi GN, Esteva FJ (2006) Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin Breast Cancer. 7:326-30
134. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD (1995) A novel putative low-affinity insulinlike growth factor-binding protein LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 5:2511-9
135. Ridley AJ (1997) The GTP-binding protein Rho. Int J Biochem Cell Biol. 29:1225-9
136. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60:5832-8
137. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD (2000) RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.
138. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD (2002) WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 21:3172-80
139. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD (2004) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res Treat. 6:110-5
140. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY (2006) Identification of celloforigin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat. 95:243-55
141. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 64:8558-65
142. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 65:2170-8
143. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869-74
144. Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, Vermeulen PB, Dirix L (2005) Identification of cell-of-origin breast tumor cell subtypes in inflammatory breast cancer by gene expression profiling. Br J Cancer. 97:1165-74
145. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 62:2507-16
146. Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, Ellison RR, Carey RW, Leone L, Weinberg V et al (1988) Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 6:261-9
147. Piccart MJ, de Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux C, Arrigo C, Cantraine F, Heuson JC (1988) Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer. 62:2501-6
148. Bedwinek J, Rao DV, Perez C, Lee J, Fineberg B (1982) Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery. Int J Radiat Oncol Biol Phys. 8:31-6
149. Conte PF, Alama A, Bertelli G, Canavese G, Carnino F, Catturich A, Di Marco E, Gardin G, Jacomuzzi A, Monzeglio C et al (1987) Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. Int J Cancer. 40:490-4
150. Hobar PC, Jones RC, Schouten J, Leitch AM, Hendler F (1988) Multimodality treatment of locally advanced breast carcinoma. Arch Surg. 123:951-5
151. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN (2007) Trends for inflammatory breast cancer: is survival improving? Oncologist. 12:904-12
152. Panades M, Olivotto IA, Speers CH, Shenkier T, Olivotto TA, Weir L, Allan SJ, Truong PT (2006) Evolving treatment strategies for inflammatory breast cancer: a populationbased survival analysis. J Clin Oncol. 20:1941-50
153. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 110:1436-44
154. Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Vilcoq JR, Bataini JP, Calle R, Fenton J, Mathieu G, Rousseau J, Asselain B (1981) Inflammatory breast carcinoma treated with a combination of chemotherapy and radiation therapy. Results of a randomized trial studying the therapeutic role of an immunotherapy with BCG. Bull Cancer. 68:171-86
155. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, Tashima CK, Gutterman JU, Yap HY, Hersh EM (1979) Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 11:325-32
156. Zylberberg B, Salat-Baroux J, Ravina JH, Dormont D, Amiel JP, Diebold P, Izrael V (1982) Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer. 49:1537-43
157. Loprinzi CL, Carbone PP, Tormey DC, Rosenbaum PR, Caldwell W, Kline JC, Steeves RA, Ramirez G (1984) Aggressive combined modality therapy for advanced localregional breast carcinoma. J Clin Oncol. 2:157-63
158. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM (1985) Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 8:134-41
159. Keiling R, Guiochet N, Calderoli H, Hurteloup P, Krzisch C (1985) Preoperative chemotherapy in the treatment of inflammatory breast cancer. Prog Clin Biol Res. 201:95-104
160. Ferreire JP (1986) Resusltats du traitement des cancers inflammatoires du sein par une association therapeutique comportant une chimiotherapie initiale. In: Jacquillat C, Weil M, Khayat D (eds) Neo-adjuvant chemotherapy. John Libbey, London
161. Israel L, Breau JL, Morere JF (1988) Neo-adjuvant chemotherapy without radiation therapy in inflammatory breast cancer carcinoma. In: Jacquillat C, Weil M, Khayat D (eds) Neo-adjuvant chemotherapy. John Libbey, Paris
162. Pourny C (1986) Traitements par chimiotherapie premiere de cancers du sein MO, localement advances (T3T4) ou s'accompagnant de signes inflammatoires locaux. In: Jaquillat C, Weil M, Khayat D (eds) Neo-adjuvant chemotherapy. John Libbey, London
163. Alberto P, Schafer P, Mermillod B (1986) Traitement combine descancers inflammatoires du sein par chimotherapie suivie de chirurgie et de radiotherapie. In: Jaquillat C, Weil M, Khayat D (eds) Neo-adjuvant chemotherapy. John Libbey, London
164. Jaquillat C, Weil M, Auclerc G (1986) Neo-adjuvant chemotherapy in the conservative management of breast cancers: study on 205 patients. In: Jaquillat C, Weil M, Khayat D (eds) Neo-adjuvant chemotherapy. John Libbey, London
165. Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ (1989) Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 17:739-45
166. Swain SM, Lippman ME. Treatment of patients with inflammatory breast cancer. Important Adv Oncol. 1989:129-50
167. Rouëssé J, Sarrazin D, Spielmann M, Le Chevalier T, Oudinot P, Guasch Jordan I, Mouriesse H, Levin FM (1989) Treatment of inflammatory cancer of the breast. Combined chemotherapy and radiotherapy. Apropos of 270 women treated at the Institut Gustave-Roussy. Bull Cancer. 76:87-92
168. Maloisel F, Dufour P, Bergerat JP, Herbrecht R, Duclos B, Boilletot A, Giron C, Jaeck D, Haennel P, Jung G et al (1990) Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 65:851-5
169. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL et al (1990) Inflammatory carcinoma of the breast: results of a combined-modality approach-M. D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 27:94-100
170. Arriagada R, Mouriesse H, Spielmann M, Mezlini A, Oudinot P, le Chevalier T, Cuvier C, Fontaine F, Travagli JP, May-Levin F et al (1990) Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 19:1207-10
171. Mourali N, Tabbane F, Muenz LR, Behi J, Ben Moussa F, Jaziri M, Levine PH (1990) Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest. 11:363-70
172. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 16:223-8
173. Fein DA, Mendenhall NP, Marsh RD, Bland KI, Copeland EM 3rd, Million RR (1994) Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 60:220-5
174. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN (1997) Combinedmodality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 40:321-9
175. Curcio LD, Rupp E, Williams WL, Chu DZ, Clarke K, Odom-Maryon T, Ellenhorn JD, Somlo G, Wagman LD (1999) Beyond palliative mastectomy in inflammatory breast cancer-a reassessment of margin status. Ann Surg Oncol. 6:249-54
176. Arthur DW, Schmidt-Ullrich RK, Friedman RB, Wazer DE, Kachnic LA, Amir C, Bear HD, Hackney MH, Smith TJ, Lawrence W Jr (1999) Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. Int J Radiat Oncol Biol Phys. 44:289-96
177. De Boer RH, Allum WH, Ebbs SR, Gui GP, Johnston SR, Sacks NP, Walsh G, Ashley S, Smith IE (2000) Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 11:1147-53